Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
F414033-1mg | 1mg | In stock | $35.90 | |
F414033-5mg | 5mg | In stock | $147.90 | |
F414033-10mg | 10mg | In stock | $246.90 | |
F414033-25mg | 25mg | In stock | $555.90 | |
F414033-50mg | 50mg | In stock | $741.90 | |
F414033-100mg | 100mg | In stock | $1,286.90 |
FGFR Inhibitors
Synonyms | BLU-554|Fisogatinib|1707289-21-1|N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide|BLU554|BLU111362|Fisogatinib [INN]|Fisogatinib [USAN]|BLU554(Fisogatinib)|X439161|BLU-111362|5Q7R99CKV2|BLU 554|X |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Fisogatinib (BLU-554) is a potent, highly-selective, oral FGFR4 inhibitor with an IC50 value of 5 nM. The IC50s for FGFR1-3 is 624-2203 nM. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of fibroblast growth factor receptor 4 |
Product Description | Information Fisogatinib (BLU-554) Fisogatinib (BLU-554) is a potent, highly-selective, oral FGFR4 inhibitor with an IC50 value of 5 nM. The IC50s for FGFR1-3 is 624-2203 nM. Targets FGFR4 (Cell-free assay) 5 nM In vitro BLU-554 exploits a unique interaction with FGFR4 to confer potency and selectivity In vivo BLU-554 is well tolerated in these tumor models. Administration of BLU-554 induces tumor regression in liver cancer models. |
ALogP | 4.229 |
---|---|
HBD Count | 2 |
Rotatable Bond | 7 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide |
---|---|
INCHI | InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1 |
InChi Key | MGZKYOAQVGSSGC-DLBZAZTESA-N |
Canonical SMILES | COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)NC4COCCC4NC(=O)C=C)Cl)OC |
Isomeric SMILES | COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)N[C@@H]4COCC[C@@H]4NC(=O)C=C)Cl)OC |
PubChem CID | 91885617 |
Molecular Weight | 503.38 |
PubChem CID | 91885617 |
---|---|
CAS Registry No. | 1707289-21-1 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K2218433 | Certificate of Analysis | Aug 25, 2022 | F414033 |
K2218434 | Certificate of Analysis | Aug 25, 2022 | F414033 |
K2218448 | Certificate of Analysis | Aug 25, 2022 | F414033 |
K2218470 | Certificate of Analysis | Aug 25, 2022 | F414033 |
K2218590 | Certificate of Analysis | Aug 25, 2022 | F414033 |
K2218591 | Certificate of Analysis | Aug 25, 2022 | F414033 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (198.65 mM); Ethanol: 2 mg/mL warmed with 50ºC Water: bath (3.97 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 198.6570782 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. |
1. Yee NS. (2018) Update in Systemic and Targeted Therapies in Gastrointestinal Oncology.. Biomedicines, 6 (1): (589-97). [PMID:29547556] |